Axonyx and Thomas Jefferson University's Collaboration To Develop Memory Enhancing Compound

Apr 18, 2001, 01:00 ET from Axonyx Inc.

    NEW YORK, April 18 /PRNewswire Interactive News Release/ -- In conjunction
 with Axonyx's (Nasdaq:   AXYX) April 11, 2001 news release featuring their new
 memory enhancing compound, you are invited to listen to the Company's
 conference call that will be broadcast live over the Internet on Wednesday,
 April 18, 2001 at 3:00 E.D.T.  Marvin S. Hausman M.D., President and CEO of
 Axonyx Inc., Robert Burford, Ph.D., Vice President, Product Development of
 Axonyx Inc. and Matthew During, M.D., Ph.D., Director of the Central Nervous
 System Gene Therapy Center and Professor of Neurosurgery at Jefferson Medical
 College will discuss Gilatide, the novel peptide that could potentially
 improve memory in healthy individuals as well as patients with dementia.
 
     What:     Axonyx and Thomas Jefferson University's collaboration to
               develop memory enhancing compound
 
     When:     Wednesday, April 18, 2001 at 3:00 pm E.D.T.
 
     Where:    http://www.videonewswire.com/AXONYX/041801/
 
      How:     Live over the Internet -- Simply log on to the web at the
               address above or go to http://www.axonyx.com.  If you do not
               have Internet access, you may dial directly into the call at
               800-711-5301.
 
     Contact:  Linda Strascina, Director of Investor Relations and Corporate
               Communications of Axonyx Inc. (212)688-4770
 
     Axonyx Inc. is a US based biotechnology company engaged in the discovery,
 acquisition and development of proprietary pharmaceutical compounds and new
 technologies useful in the diagnosis and treatment of Alzheimer's Disease,
 other memory disorders and Mad Cow Disease.  Phenserine, the Company's lead
 Alzheimer's Disease drug, is in a Phase II proof of concept clinical trial.
 
     If you are unable to participate during the live webcast, the call will be
 archived on the Web site http://www.axonyx.com.  To access the replay, click
 on the web cast link on the homepage.
     (Minimum Requirements to listen to broadcast: The RealPlayer software,
 downloadable free from httpz://www.real.com/products/player/index.html, and at
 least a 14.4Kbps connection to the Internet.  If you experience problems
 listening to the broadcast, send an email to webmaster@vdat.com.)
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X66847046
 
 

SOURCE Axonyx Inc.
    NEW YORK, April 18 /PRNewswire Interactive News Release/ -- In conjunction
 with Axonyx's (Nasdaq:   AXYX) April 11, 2001 news release featuring their new
 memory enhancing compound, you are invited to listen to the Company's
 conference call that will be broadcast live over the Internet on Wednesday,
 April 18, 2001 at 3:00 E.D.T.  Marvin S. Hausman M.D., President and CEO of
 Axonyx Inc., Robert Burford, Ph.D., Vice President, Product Development of
 Axonyx Inc. and Matthew During, M.D., Ph.D., Director of the Central Nervous
 System Gene Therapy Center and Professor of Neurosurgery at Jefferson Medical
 College will discuss Gilatide, the novel peptide that could potentially
 improve memory in healthy individuals as well as patients with dementia.
 
     What:     Axonyx and Thomas Jefferson University's collaboration to
               develop memory enhancing compound
 
     When:     Wednesday, April 18, 2001 at 3:00 pm E.D.T.
 
     Where:    http://www.videonewswire.com/AXONYX/041801/
 
      How:     Live over the Internet -- Simply log on to the web at the
               address above or go to http://www.axonyx.com.  If you do not
               have Internet access, you may dial directly into the call at
               800-711-5301.
 
     Contact:  Linda Strascina, Director of Investor Relations and Corporate
               Communications of Axonyx Inc. (212)688-4770
 
     Axonyx Inc. is a US based biotechnology company engaged in the discovery,
 acquisition and development of proprietary pharmaceutical compounds and new
 technologies useful in the diagnosis and treatment of Alzheimer's Disease,
 other memory disorders and Mad Cow Disease.  Phenserine, the Company's lead
 Alzheimer's Disease drug, is in a Phase II proof of concept clinical trial.
 
     If you are unable to participate during the live webcast, the call will be
 archived on the Web site http://www.axonyx.com.  To access the replay, click
 on the web cast link on the homepage.
     (Minimum Requirements to listen to broadcast: The RealPlayer software,
 downloadable free from httpz://www.real.com/products/player/index.html, and at
 least a 14.4Kbps connection to the Internet.  If you experience problems
 listening to the broadcast, send an email to webmaster@vdat.com.)
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X66847046
 
 SOURCE  Axonyx Inc.